Drugs / Vi-DT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04204096 | Feb → Sep 2020 | typhoid fever | International Vaccine Institute | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-DT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04204096 ↗ |
| Modality | Vaccine | “Vi-DT Typhoid Conjugate Vaccine” NCT04204096 ↗ |
| Route | Intramuscular | “Mode of Administration: 0.5 mL by intramuscular injection” NCT04204096 ↗ |